Analysis
Attovia Therapeutics priced its IPO at $17 a share, raising roughly $212.5 million, and began trading on Nasdaq today under the ticker ATTO. The Phase 1 biotech, developing biologics for immune-mediated diseases using a biparatopic nanobody platform licensed from Alamar Biosciences, lists with a fully diluted market value near $649 million at the midpoint of its marketed range.
The company's cap table carries real institutional weight: Goldman Sachs affiliates, Deep Track Capital, Frazier Life Sciences and venBio are all major shareholders, and Attovia had already raised a cumulative $255.8 million privately as of March 2026 before going public. Its lead candidate, ATTO-1310, targets IL-31 for chronic pruritus and atopic dermatitis and has completed Phase 1 dosing in both healthy volunteers and patients; a second bispecific candidate and a third trispecific candidate for inflammatory bowel disease are following in earlier-stage development.
Attovia is part of what analysts have started calling a reopening biotech IPO window in 2026, alongside fellow filer Latigo Biotherapeutics (also in this issue) and other clinical-stage names testing renewed investor appetite for pre-revenue biotech after a multi-year drought that followed the 2021 biotech IPO peak. Renaissance Capital and other IPO trackers have specifically framed this cohort as a test of whether generalist crossover investors are back for early-stage biotech risk, not just late-stage, de-risked assets.
The comp set matters here: biotech IPOs since 2022 have had a mixed record post-listing, with many trading well below their offer price within the first year regardless of trial progress, largely due to macro rate sensitivity for pre-revenue, cash-burning companies. Attovia's Goldman and Deep Track backing gives it a stronger institutional anchor than many recent biotech debuts, which should help stabilize aftermarket trading in the first weeks.
What to watch: Attovia's stock performance in its first 30 days as an early read on generalist investor appetite for Phase 1 biotech risk, and whether Latigo and the rest of this week's S-1 cohort (Lyntris, First Breach) price and trade with similar institutional support.